# Jonathan I. Silverberg

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jonathan-i-silverberg/

## Facts

| Field | Value |
| --- | --- |
| Citations | 52,728 |
| Field | Dermatology and Skin Diseases |
| h-index | 102 |
| i10-index | 538 |
| Last Known Institution | George Washington University |
| OpenAlex ID | https://openalex.org/A5011739266 |
| ORCID iD | 0000-0003-3686-7805 |
| Works | 1,220 |

## Researcher papers

Showing 12 of 21.

- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Global Skin Disease Morbidity and Mortality](https://scholariq.org/papers/global-skin-disease-morbidity-and-mortality/)
- [Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis](https://scholariq.org/papers/dupilumab-progressively-improves-systemic-and-cutaneous-abnormalities-in/)
- [Patient burden and quality of life in atopic dermatitis in US adults](https://scholariq.org/papers/patient-burden-and-quality-of-life-in-atopic-dermatitis-in-us-adults/)
- [Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population–based study](https://scholariq.org/papers/adult-eczema-prevalence-and-associations-with-asthma-and-other-health-and/)
- [Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis](https://scholariq.org/papers/abrocitinib-versus-placebo-or-dupilumab-for-atopic-dermatitis/)
- [Atopic dermatitis in the pediatric population](https://scholariq.org/papers/atopic-dermatitis-in-the-pediatric-population/)
- [Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population](https://scholariq.org/papers/atopic-dermatitis-in-america-study-a-cross-sectional-study-examining-the/)
- [Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-abrocitinib-in-patients-with-moderate-to-severe-atopic/)
- [Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/safety-and-efficacy-of-upadacitinib-in-combination-with-topical-corticosteroids/)
- [Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials](https://scholariq.org/papers/baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-and-inadequate/)
- [Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder](https://scholariq.org/papers/increasing-comorbidities-suggest-that-atopic-dermatitis-is-a-systemic-disorder/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Food Allergy and Anaphylaxis Research](https://scholariq.org/topics/food-allergy-and-anaphylaxis-research/)

## Researcher university

- [George Washington University](https://scholariq.org/institutions/george-washington-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.